论文部分内容阅读
目的：探讨早期强烈诱导缓解方案提高晚期淋巴母细胞性淋巴瘤的完全缓解 (complete remission,CR)率。方法： 11例Ⅲ /Ⅳ期初治淋巴母细胞性淋巴瘤，诱导缓解期接受 CVDLP方案化疗：环磷酰胺 1000 mg/m2 d1，长春新碱 1.5 mg/m2 d1、 d8、 d15、 d21,阿霉素 40 mg/m2 d1、 d2、 d21，门冬酰胺酶 10 000 U/m2 d15～ 24，强的松 60 mg/m2 d1～ 28，第 15天逐步减量。氨甲喋呤加阿糖胞苷鞘内注射每周一次，共 4次。第 28～ 33天评价疗效。同时回顾性比较 9例初治Ⅲ /Ⅳ期淋巴母细胞性淋巴瘤，采用标准 CHOP方案治疗两疗程后的疗效（第 35天）。结果： CVDLP方案组 10例初治病人获得完全缓解 , 1例病人获得部分缓解 ,完全缓解率达 90.9％ ;10例病人出现Ⅳ级血液毒性， 1例病人出现Ⅲ级血液毒性（ WHO标准）。 CHOP组 3例完全缓解， 5例部分缓解， 1例微效 ,完全缓解率达 33％ ;3例病人出现Ⅲ级血液毒性， 6例病人出现Ⅱ级血液毒性。结论：对于晚期淋巴母细胞瘤，诱导缓解期采用 CVDLP方案获得的早期完全缓解率明显高于 CHOP方案，血液毒性也比 CHOP大，但加强支持疗法，此诱导缓解方案安全可行。
OBJECTIVE: To investigate the early acute remission induction regimen to improve the complete remission (CR) rate of advanced lymphoblastic lymphoma. METHODS: Eleven patients with lymphoblastic lymphoma at the beginning of stage III/IV were treated with CVDLP during remission induction: cyclophosphamide 1000 mg/m2 d1, vincristine 1.5 mg/m2 d1, d8, d15, d21, and For 40 mg/m2 d1, d2, and d21, asparaginase 10 000 U/m2 d15 to 24, prednisone 60 mg/m2 d1 to 28, and gradually decrease on the 15th day. Methotrexate plus cytarabine was injected intraperitoneally once a week for 4 times. 28 to 33 days to evaluate efficacy. At the same time, retrospective comparison of 9 cases of de novo III/IV lymphoblastic lymphoma was performed with standard CHOP regimen after two courses of treatment (day 35). Results: 10 patients in the CVDLP group received complete remission, 1 patient achieved partial remission, and complete remission rate reached 90.9%; 10 patients developed grade IV hematologic toxicity, and 1 patient developed grade III hematologic toxicity (the WHO standard) . The CHOP group achieved complete remission in 3 cases, partial remission in 5 cases, minor effect in 1 case, complete remission rate of 33%, grade III hematologic toxicity in 3 patients, and grade II hematologic toxicity in 6 patients. CONCLUSIONS: For advanced lymphoblastoma, the early complete remission rate achieved with CVDLP during remission was significantly higher than that with CHOP, and hematologic toxicity was also greater than CHOP. However, with supportive therapies, the induction of remission was safe and feasible.